This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ahead of Neurocrine (NBIX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMLX vs. NBIX: Which Stock Is the Better Value Option?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Neurocrine (NBIX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Neurocrine (NBIX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neurocrine (NBIX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Q3 GDP Excite Investors?
by John Blank
The recession bears will never go away. The bulls can take advantage of that.
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank
by Zacks Equity Research
BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.
Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD
by Zacks Equity Research
The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.
AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.
Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse
by Zacks Equity Research
The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.
Will Big Stocks Make Big Headlines? Global Week Ahead
by John Blank
This trading week might offer some reassurance -- that both households and businesses are holding up -- in an uncertain macro environment.
Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns
by Vaishali Doshi
Here are four top-performing liquid stocks, Neurocrine Biosciences (NBIX), GigaCloud Technology (GCT), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for robust returns.
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.